Investment Thesis
Indaptus Therapeutics is a pre-revenue biotech company with no income generation, burning $7M annually in operating cash against only $1.5M in cash reserves, implying severe financial distress within 2-3 months. Negative net income of -$2.5M, zero revenue, and stockholders' equity of just $1.2M indicate the company lacks financial runway for continued operations without immediate capital infusion or transformative clinical success.
Strengths
- Zero long-term debt reduces fixed obligations
- Current ratio of 2.34x shows short-term liquidity is not immediately critical
- EPS deterioration moderation (52% YoY improvement, though still negative) suggests potential operational stabilization efforts
Risks
- Critical cash runway: $1.5M cash against $7M annual operating burn leaves approximately 2-3 months of operations before insolvency
- Zero revenue generation indicates no commercial traction or approved products
- Deeply negative equity (-203.6% ROE) signals potential shareholder dilution or capital restructuring risk
- Rapidly deteriorating net income (-38.8% YoY) despite modest EPS improvement reflects worsening fundamentals masked by share dilution
- Minimal stockholders' equity of $1.2M provides no cushion for operational losses
Key Metrics to Watch
- Cash balance trend and monthly burn rate (critical for survival assessment)
- Announcements of capital raises, financing, or partnership deals
- Clinical trial progress or regulatory milestone announcements affecting asset value
Financial Metrics
Revenue
N/A
Net Income
-2.5M
EPS (Diluted)
$-0.23
Free Cash Flow
-7.0M
Total Assets
9.3M
Cash
1.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-203.6%
ROA
-27.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.34x
Quick Ratio
2.34x
Debt/Equity
0.00x
Debt/Assets
36.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:11:39.361181 |
Data as of: 2026-03-31 |
Powered by Claude AI